JP2013518037A5 - - Google Patents

Download PDF

Info

Publication number
JP2013518037A5
JP2013518037A5 JP2012549376A JP2012549376A JP2013518037A5 JP 2013518037 A5 JP2013518037 A5 JP 2013518037A5 JP 2012549376 A JP2012549376 A JP 2012549376A JP 2012549376 A JP2012549376 A JP 2012549376A JP 2013518037 A5 JP2013518037 A5 JP 2013518037A5
Authority
JP
Japan
Prior art keywords
growth hormone
seq
hormone compound
single point
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012549376A
Other languages
English (en)
Japanese (ja)
Other versions
JP5980689B2 (ja
JP2013518037A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2011/050909 external-priority patent/WO2011089250A2/en
Publication of JP2013518037A publication Critical patent/JP2013518037A/ja
Publication of JP2013518037A5 publication Critical patent/JP2013518037A5/ja
Application granted granted Critical
Publication of JP5980689B2 publication Critical patent/JP5980689B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012549376A 2010-01-22 2011-01-24 安定な成長ホルモン化合物 Expired - Fee Related JP5980689B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US29730510P 2010-01-22 2010-01-22
US61/297,305 2010-01-22
EP10151405 2010-01-22
EP10151405.7 2010-01-22
CNPCT/CN2010/001120 2010-07-23
CN2010001120 2010-07-23
US37860210P 2010-08-31 2010-08-31
US61/378,602 2010-08-31
PCT/EP2011/050909 WO2011089250A2 (en) 2010-01-22 2011-01-24 Stable growth hormone compounds

Publications (3)

Publication Number Publication Date
JP2013518037A JP2013518037A (ja) 2013-05-20
JP2013518037A5 true JP2013518037A5 (enExample) 2014-03-06
JP5980689B2 JP5980689B2 (ja) 2016-08-31

Family

ID=44166478

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012549376A Expired - Fee Related JP5980689B2 (ja) 2010-01-22 2011-01-24 安定な成長ホルモン化合物

Country Status (11)

Country Link
US (1) US9211342B2 (enExample)
EP (1) EP2525833A2 (enExample)
JP (1) JP5980689B2 (enExample)
AU (1) AU2011208620B2 (enExample)
BR (1) BR112012018162A2 (enExample)
CA (1) CA2787895A1 (enExample)
IL (1) IL220648A0 (enExample)
MX (1) MX338357B (enExample)
RU (1) RU2012134974A (enExample)
WO (1) WO2011089250A2 (enExample)
ZA (1) ZA201205385B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX345736B (es) 2010-01-22 2017-02-14 Novo Nordisk Healthcare Ag Hormonas de crecimiento con eficacia in vivo prolongada.
US9211342B2 (en) 2010-01-22 2015-12-15 Novo Nordisk Healthcare Ag Stable growth hormone compounds resistant to proteolytic degradation
CN103269720A (zh) * 2010-07-22 2013-08-28 诺沃—诺迪斯克保健股份有限公司 生长激素缀合物
WO2014139994A1 (en) 2013-03-11 2014-09-18 Novo Nordisk Health Care Ag Growth hormone compounds
CN105120887A (zh) 2013-04-05 2015-12-02 诺和诺德保健股份有限公司 生长激素化合物制剂
WO2015036553A1 (en) 2013-09-16 2015-03-19 Novo Nordisk Health Care Ag Thiol functionalized polymers
EP3079722B1 (en) 2013-12-13 2021-03-24 Novo Nordisk Health Care AG Method for thioether conjugation of proteins
US10286079B2 (en) 2015-09-22 2019-05-14 The Regents Of The University Of California Modified cytotoxins and their therapeutic use
AU2016326392B2 (en) 2015-09-22 2021-02-11 The Regents Of The University Of California Modified cytotoxins and their therapeutic use
MA43348A (fr) 2015-10-01 2018-08-08 Novo Nordisk As Conjugués de protéines
KR20180003677A (ko) * 2016-06-30 2018-01-10 주식회사 크레아플래닛 인간 성장호르몬 변이 단백질 또는 이의 트랜스페린 융합 단백질을 유효성분으로 포함하는 약학적 조성물

Family Cites Families (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8504099D0 (en) 1985-02-18 1985-03-20 Wellcome Found Physiologically active substances
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
GB8610551D0 (en) 1986-04-30 1986-06-04 Hoffmann La Roche Polypeptide & protein derivatives
JPH0665280B2 (ja) 1987-03-04 1994-08-24 味の素株式会社 タンパクゲル化剤及びそれを用いるタンパクのゲル化方法
ATE198353T1 (de) 1988-08-24 2001-01-15 American Cyanamid Co Stabilisierung von somatotropinen durch modifikation von cystein-resten durch orts- spezifische mutagenese oder chemische derivatisierung
ATE189526T1 (de) 1988-10-28 2000-02-15 Genentech Inc Verfahren zum nachweis von aktiven domänen und aminosäureresten in polypeptiden und hormonvarianten
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
US5534617A (en) 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
JPH04504246A (ja) 1989-03-20 1992-07-30 ザ・ジェネラル・ホスピタル・コーポレーション インシュリン刺激ホルモン
US5101018A (en) 1989-06-12 1992-03-31 International Minerals & Chemical Corp. Method for recovering recombinant proteins
DE3930696A1 (de) 1989-09-14 1991-03-28 Hoechst Ag Gallensaeurederivate, verfahren zu ihrer herstellung, verwendung als arzneimittel
WO1991011457A1 (en) 1990-01-24 1991-08-08 Buckley Douglas I Glp-1 analogs useful for diabetes treatment
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
US5951972A (en) 1990-05-04 1999-09-14 American Cyanamid Company Stabilization of somatotropins and other proteins by modification of cysteine residues
JP2849773B2 (ja) 1990-08-27 1999-01-27 天野製薬株式会社 ストレプトミセス属由来のトランスグルタミナーゼの製造法
DK220890D0 (da) 1990-09-14 1990-09-14 Ole Buchardt Fremgangsmaade til fremstilling af c-terminalt amiderede peptider
JP3267293B2 (ja) * 1990-12-03 2002-03-18 ジェネンテク，インコーポレイテッド 改変された結合性を有する変異タンパク質の豊富化法
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
IT1251895B (it) * 1991-09-27 1995-05-26 Eniricerche Spa Mutanti dell'ormone della crescita umano e loro impiego
DE69333718T2 (de) 1992-01-14 2005-12-01 Ajinomoto Co., Inc. Gen, das für eine Fisch-Transglutaminase kodiert
ES2153385T5 (es) 1992-07-31 2008-09-01 Genentech, Inc. Composicion acuosa a base de hormona del crecimiento humana.
ZA936811B (en) 1992-10-28 1995-03-15 Upjohn Co Somatotropin modifications
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
WO1995020662A1 (en) 1994-01-28 1995-08-03 Ajinomoto Co., Inc. Transglutaminase originating in japanese oyster
JP3720363B2 (ja) 1994-08-26 2005-11-24 ノボザイムス アクティーゼルスカブ 微生物のトランスグルタミナーゼ、それらの産生及び使用
US6010871A (en) 1994-09-29 2000-01-04 Ajinomoto Co., Inc. Modification of peptide and protein
DE4437604A1 (de) 1994-10-21 1996-04-25 Basf Ag Konjugate aus einem Poly- oder Oligopeptid und einer niedermolekularen lipophilen Verbindung
ATE248219T1 (de) 1995-01-19 2003-09-15 Novozymes As Transglutaminasen aus oomyzeten
JP3669390B2 (ja) 1995-02-09 2005-07-06 味の素株式会社 バチルス属細菌由来のトランスグルタミナーゼ
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
DE851925T1 (de) 1995-09-21 2003-08-14 Genentech Inc., San Francisco Varianten des menschlichen wachstumshormons
US20020077461A1 (en) 1996-04-24 2002-06-20 Soren Bjorn Pharmaceutical formulation
WO1998008872A1 (en) 1996-08-30 1998-03-05 Novo Nordisk A/S Glp-2 derivatives
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
ES2283025T3 (es) 1996-08-30 2007-10-16 Novo Nordisk A/S Derivados de glp-1.1.
EP0950665A4 (en) 1996-09-26 2004-05-06 Ajinomoto Kk PHYSIOLOGICALLY ACTIVE MODIFIED PROTEINS AND DRUG COMPOSITIONS CONTAINING THEM
US5985627A (en) 1997-02-28 1999-11-16 Carlsberg Laboratory Modified carboxypeptidase
JPH1156378A (ja) * 1997-06-11 1999-03-02 Nippon Chem Res Kk 変異型ヒト成長ホルモンとその用途
PT996629E (pt) 1997-06-25 2006-12-29 Applied Research Systems Análogos de hormonas glicoproteicas reticulados com ligações dissulfito, sua preparação e utilização
EP1012184B1 (en) 1997-07-14 2007-10-10 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
JPH1192499A (ja) * 1997-09-22 1999-04-06 Sumitomo Pharmaceut Co Ltd ヒト成長ホルモン変異体
US6136536A (en) 1997-10-29 2000-10-24 Genetics Institute, Inc. Rapid generation of stable mammalian cell lines producing high levels of recombinant proteins
AU2610799A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S Glp-1 derivatives with helix-content exceeding 25 per cent, forming partially structured micellar-like aggregates
JP2002504527A (ja) 1998-02-27 2002-02-12 ノボ ノルディスク アクティーゼルスカブ 部分的に組織化したミセル様凝集物を形成する２５％を越えるヘリックス成分を有するｇｌｐ−２誘導体
WO1999043705A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S N-terminally truncated glp-1 derivatives
WO1999043708A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
DE69942307D1 (de) 1998-02-27 2010-06-10 Novo Nordisk As N-terminal veränderte glp-1 abkömmlinge
US6656922B2 (en) 1998-05-28 2003-12-02 Mediplex Corporation, Korea Oral delivery of macromolecules
US6358705B1 (en) 1998-07-16 2002-03-19 Novo Nordisk A/S Method of making proteins in transformed yeast cells
SG125915A1 (en) 1998-12-07 2006-10-30 Sod Conseils Rech Applic Analogues of glp-1
US6329336B1 (en) 1999-05-17 2001-12-11 Conjuchem, Inc. Long lasting insulinotropic peptides
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
WO2001004287A1 (en) 1999-07-07 2001-01-18 Maxygen Aps A method for preparing modified polypeptides
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
GB2355009A (en) 1999-07-30 2001-04-11 Univ Glasgow Peptides conjugated to bile acids/salts
US20040001827A1 (en) 2002-06-28 2004-01-01 Dennis Mark S. Serum albumin binding peptides for tumor targeting
EP1250126A2 (en) 2000-01-11 2002-10-23 Novo Nordisk A/S Transepithelial delivery of glp-1 derivatives
WO2001058935A2 (en) 2000-02-11 2001-08-16 Maxygen Aps FACTOR VII OR VIIa-LIKE MOLECULES
CA2405550A1 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
NZ522847A (en) * 2000-05-16 2004-11-26 Bolder Biotechnology Inc Methods for refolding proteins containing free cysteine residues
US20020142964A1 (en) 2000-11-02 2002-10-03 Nissen Torben Lauesgaard Single-chain polypeptides
DK1355942T3 (da) 2000-12-07 2008-11-17 Lilly Co Eli GLP-1-fusionsproteiner
US20060183197A1 (en) 2001-01-11 2006-08-17 Andersen Kim V Variant growth hormone molecules conjugated with macromolecules compounds
AU2002219021A1 (en) 2001-01-11 2002-07-24 Maxygen Aps Variant growth hormone molecules conjugated with macromolecular compounds
FR2819810B1 (fr) 2001-01-23 2004-05-28 Pf Medicament Peptides non glycosyles derives de la proteine g du vrs et leur utilisation dans un vaccin
US6858580B2 (en) 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
EP2110385A1 (en) 2001-06-14 2009-10-21 The Scripps Research Institute Stabilized factor VIII with engineered disulfide bonds
DK1412384T3 (da) 2001-06-28 2008-04-28 Novo Nordisk As Stabil formulering af modificeret GLP-1
EP1423136A4 (en) 2001-08-10 2007-07-25 Epix Pharm Inc POLYPEPTIDE CONJUGATES HAVING INCREASED CIRCULATION HALF-VIES
AR036711A1 (es) 2001-10-05 2004-09-29 Bayer Corp Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico
JP2005518786A (ja) 2001-11-12 2005-06-30 ユニバーシティ カレッジ カーディフ コンサルタンツ リミテッド ヒトにおける成長ホルモン変異とその用途
WO2003044056A2 (en) 2001-11-20 2003-05-30 Pharmacia Corporation Chemically-modified human growth hormone conjugates
JP2003199569A (ja) 2001-12-17 2003-07-15 Food Industry Research & Development Inst ストレプトベルティシリウム・ラダカヌムのトランスグルタミナーゼ遺伝子及び該遺伝子によってコードされるトランスグルタミナーゼ
FR2836382B1 (fr) 2002-02-28 2004-08-13 Biomerieux Sa Nouveaux agents de couplages, leurs conjugues, ainsi que l'utilisation de ces conjugues dans des methodes de diagnostic
EP1587944A4 (en) 2002-03-01 2007-03-21 Dyax Corp KDR AND VEGF / KDR BINDING PEPTIDES AND THEIR USE FOR DIAGNOSTIC AND THERAPEUTIC PURPOSES
US20050164925A1 (en) 2002-04-10 2005-07-28 Joseph Anthony Jakubowski And Thurman Dwight Mc Kinney Treatment of gastroparesis
PL373728A1 (en) 2002-04-30 2005-09-05 Maxygen Holdings Ltd. Factor vii or viia polypeptide variants
US7611700B2 (en) 2002-09-09 2009-11-03 Hanall Pharmaceuticals, Co., Ltd. Protease resistant modified interferon alpha polypeptides
EP2067483A1 (en) 2003-02-19 2009-06-10 Ipsen Pharma Analogues of GLP-1
JP2007524584A (ja) 2003-05-09 2007-08-30 ノボ　ノルディスク　アクティーゼルスカブ 肥満の治療に使用するペプチド
EP1654004A2 (en) 2003-08-08 2006-05-10 Novo Nordisk A/S Synthesis and application of new structural well defined branched polymers as conjugating agents for peptides
RU2401276C2 (ru) 2003-09-19 2010-10-10 Ново Нордиск А/С Производные глюкагон-подобного пептида-1 (glp-1)
EP1667724A2 (en) 2003-09-19 2006-06-14 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
CN100444898C (zh) 2003-09-19 2008-12-24 诺沃挪第克公司 治疗肽的清蛋白结合型衍生物
TW200526254A (en) 2003-09-19 2005-08-16 Novo Nordisk As Novel GLP-1 derivatives
CN100580087C (zh) 2003-10-10 2010-01-13 诺和诺德医疗保健公司 肽的缀合
CN101665538A (zh) 2003-12-18 2010-03-10 诺沃挪第克公司 与白蛋白样物质相连的新glp-1类似物
ATE461217T1 (de) 2003-12-18 2010-04-15 Novo Nordisk As Glp-1-verbindungen
CA2552043A1 (en) 2004-01-21 2005-08-04 Novo Nordisk A/S Transglutaminase mediated conjugation of peptides
BRPI0507159A (pt) 2004-02-02 2007-06-26 Ambrx Inc polipeptìdeos em feixe de quatro hélices humanos modificados e seus usos
UA89781C2 (uk) 2004-04-07 2010-03-10 Арес Трейдінг С.А. Рідкий склад гормона росту
US7906137B2 (en) 2004-05-21 2011-03-15 Mediplex Corporation, Korea Delivery agents for enhancing mucosal absorption of therapeutic agents
MXPA06015049A (es) 2004-07-08 2007-02-08 Novo Nordisk As Marcadores prolongadores de polipeptidos que comprenden una porcion tetrazol.
US20090176967A1 (en) 2004-08-02 2009-07-09 Novo Nordisk Healthcare A/G Conjugation of FVII
US7893017B2 (en) 2004-10-07 2011-02-22 Novo Nordisk A/S Protracted GLP-1 compounds
US7998930B2 (en) * 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
CA2594561C (en) 2004-12-22 2014-12-23 Ambrx, Inc. Formulations of human growth hormone comprising a non-naturally encoded amino acid
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
MX2007011307A (es) 2005-03-18 2007-10-08 Novo Nordisk As Compuestos de glp-1 extendidos.
EP1863537A2 (en) 2005-03-18 2007-12-12 Novo Nordisk A/S Dimeric peptide agonists of the glp-1 receptor
WO2006134173A2 (en) 2005-06-17 2006-12-21 Novo Nordisk Health Care Ag Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine
WO2007020291A1 (en) 2005-08-18 2007-02-22 Novo Nordisk Health Care Ag Improving transglutaminase substrate specificity
US8293708B2 (en) 2005-08-30 2012-10-23 Novo Nordisk Health Care A/G Liquid formulations N-terminal serine of pegylated growth hormone
CN1939534B (zh) 2005-09-27 2010-12-01 长春金赛药业股份有限公司 含有人生长激素或人粒细胞巨噬细胞刺激因子的用于治疗损伤和溃疡的外用制剂
CN101384711A (zh) * 2006-01-19 2009-03-11 Ambrx公司 具有经调节的免疫原性的非天然氨基酸多肽
EP1986694B1 (en) 2006-02-14 2015-06-10 Novo Nordisk Health Care AG Coupling of polypeptides at the c-terminus
WO2008003750A2 (en) 2006-07-07 2008-01-10 Novo Nordisk Health Care Ag New protein conjugates and methods for their preparation
ES2745411T3 (es) 2006-07-27 2020-03-02 Wang Nai Fang Compuestos y composiciones de arilsulfanilo para administración de agentes activos
JP2010500886A (ja) 2006-08-18 2010-01-14 ノボ ノルディスク ヘルス ケア アーゲー 改善された特異性を有するトランスグルタミナーゼ変異体
US20080095837A1 (en) 2006-08-31 2008-04-24 Emisphere Technologies, Inc. Human growth hormone formulations
PL2059260T3 (pl) 2006-08-31 2014-03-31 Novartis Ag Kompozycja farmaceutyczna obejmująca hGH do dostarczania doustnego
US8383852B2 (en) 2007-02-16 2013-02-26 Emisphere Technologies, Inc. Compounds having a cyclic moiety and compositions for delivering active agents
WO2008112836A2 (en) 2007-03-15 2008-09-18 Novartis Ag Pharmaceutical composition comprising human growth hormon
WO2009030771A1 (en) 2007-09-05 2009-03-12 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
MX2011000847A (es) 2008-08-06 2011-02-25 Novo Nordisk Healthcare Ag Proteinas conjugadas con eficacia prolongada in vivo.
EP2324056A1 (en) 2008-09-09 2011-05-25 Novo Nordisk Health Care AG Growth hormone conjugate with increased stability
US8637647B2 (en) 2008-09-12 2014-01-28 Novo Nordisk A/S Method of acylating a peptide or protein
CN102292349B (zh) 2009-01-22 2016-04-13 诺沃—诺迪斯克保健股份有限公司 稳定的生长激素化合物
CN102333788A (zh) 2009-02-19 2012-01-25 诺沃—诺迪斯克有限公司 因子viii的修饰
CN102612376A (zh) 2009-08-06 2012-07-25 诺沃-诺迪斯克保健股份有限公司 具有延长的体内功效的生长激素
US9211342B2 (en) 2010-01-22 2015-12-15 Novo Nordisk Healthcare Ag Stable growth hormone compounds resistant to proteolytic degradation
MX345736B (es) 2010-01-22 2017-02-14 Novo Nordisk Healthcare Ag Hormonas de crecimiento con eficacia in vivo prolongada.
WO2011101261A2 (en) 2010-02-16 2011-08-25 Novo Nordisk A/S Purification method

Similar Documents

Publication Publication Date Title
JP2013518037A5 (enExample)
RU2012134974A (ru) Стабилизированное соединение гормона роста
WO2009033665A3 (en) Use of a rgd-peptide and/or parathyroid hormone (1-34 ) as anti-hiv agent
WO2012122340A8 (en) Soluble guanylate cyclase activators
WO2009033711A3 (en) Use of glp-1 as a therapeutic agent
WO2009040036A3 (en) Use of a galanin peptide as a therapeutic agent
AR081427A1 (es) Metodo para preparar anticuerpos con propiedades mejoradas
WO2009033805A3 (en) Use of somatostatin-14 as a therapeutic agent
JP2013530974A5 (enExample)
WO2009043466A3 (en) Therapeutic use of the peptide gluten exorphin a5
WO2009046847A3 (en) Use of peptide ll-37 as a therapeutic agent
WO2011080102A3 (en) Glp-1 analogues and derivatives
WO2009043463A3 (en) Use of gluten exorphin c : as a therapeutic agent
JP2012515748A5 (enExample)
WO2009033760A3 (en) Use of fibronectin fragment (196-203 ) as a therapeutic agent
WO2009033667A3 (en) Use of a peptide as a therapeutic agent
JP2013515055A5 (enExample)
WO2009033681A3 (en) Cyclo-argd as a therapeutic agent
PH12018502465A1 (en) Mic-1 compounds and use thereof
JP2016523891A5 (enExample)
WO2009033737A3 (en) Use of gluten exorphin c : as a therapeutic agent
NZ599604A (en) Synthetic myostatin peptide antagonists
JP2013530702A5 (enExample)
WO2009033778A3 (en) Mage-3 antigen and others for use as a therapeutic agent
PH12019550241A1 (en) Mic-1 compounds and uses thereof